North Estonia Medical Centre is an Estonian medical centre which main building is located in Mustamäe, Tallinn. North Estonia Medical Centre Foundation was established on 25 July 2001. The centre consists of 7 clinics and 32 specialist centres. In total, over 4800 people are working there.

During the past decade, North Estonia Medical Centre Foundation conducted 66 clinical trials. In the 10-year time frame, 66 clinical trials started and 31 clinical trials were completed, i.e. on average, 47% percent of trials that started reached the finish line to date. In the past 5 years, 32 clinical trials started and 20 clinical trials were completed. i.e. 62.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "North Estonia Medical Centre Foundation" #1 sponsor was "Hoffmann-La Roche" with 19 trials, followed by "Amgen" with 8 trials sponsored, "Pfizer" with 5 trials sponsored, "Takeda" with 5 trials sponsored and "Galapagos NV" with 5 trials sponsored. Other sponsors include 49 different institutions and companies that sponsored additional 49 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "North Estonia Medical Centre Foundation" #1 collaborator was "North Estonia Medical Centre" with 3 trials as a collaborator, "Tartu University Hospital" with 3 trials as a collaborator, "AstraZeneca" with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator and "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)" with 1 trials as a collaborator. Other collaborators include 30 different institutions and companies that were collaborators in the rest 40 trials.

According to Clinical.Site data, the most researched conditions in "North Estonia Medical Centre Foundation" are "Psoriatic Arthritis" (5 trials), "Ulcerative Colitis" (5 trials), "Breast Cancer" (4 trials), "Urothelial Carcinoma" (4 trials) and "Acute Myocardial Infarction" (3 trials). Many other conditions were trialed in "North Estonia Medical Centre Foundation" in a lesser frequency.

Most popular intervention types in "North Estonia Medical Centre Foundation" are "Drug" (69 trials), "Other" (17 trials), "Biological" (7 trials), "Device" (4 trials) and "Procedure" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (23 trials), "Etrolizumab" (4 trials), "Adalimumab" (3 trials), "Atezolizumab" (3 trials) and "Cisplatin" (3 trials). Other intervention names were less common.

The vast majority of trials in "North Estonia Medical Centre Foundation" are 82 trials for "All" genders, 8 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "North Estonia Medical Centre Foundation". undefined are not yet recruiting, 19 are recruiting, 11 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 47 completed trials in North Estonia Medical Centre Foundation, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in North Estonia Medical Centre Foundation, 2 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 54 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 9 trials that are defined as “Not Applicable".

North Estonia Medical Centre Foundation has several departments that took part in Clinical trials: "North Estonia Medical Centre, Dept of Haematology" - 2 trials